Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ENOV NASDAQ:IRMD NASDAQ:SLNO NASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENOVEnovis$32.35-2.9%$29.81$25.47▼$49.83$1.85B1.681.17 million shs753,842 shsIRMDiRadimed$71.51+0.1%$66.57$46.86▼$74.43$907.83M1.0244,192 shs27,074 shsSLNOSoleno Therapeutics$51.72+4.0%$75.66$41.50▼$90.32$2.75B-2.721.20 million shs1.36 million shsTMDXTransMedics Group$120.61+1.2%$115.82$55.00▼$169.29$4.07B2.181.30 million shs489,174 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENOVEnovis+2.94%+6.80%+12.65%+8.50%-21.63%IRMDiRadimed-0.21%-0.60%+1.53%+22.26%+45.66%SLNOSoleno Therapeutics-2.85%-29.20%-30.60%-37.38%-5.83%TMDXTransMedics Group+4.25%+10.04%-6.59%-3.91%-21.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENOVEnovis$32.35-2.9%$29.81$25.47▼$49.83$1.85B1.681.17 million shs753,842 shsIRMDiRadimed$71.51+0.1%$66.57$46.86▼$74.43$907.83M1.0244,192 shs27,074 shsSLNOSoleno Therapeutics$51.72+4.0%$75.66$41.50▼$90.32$2.75B-2.721.20 million shs1.36 million shsTMDXTransMedics Group$120.61+1.2%$115.82$55.00▼$169.29$4.07B2.181.30 million shs489,174 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENOVEnovis+2.94%+6.80%+12.65%+8.50%-21.63%IRMDiRadimed-0.21%-0.60%+1.53%+22.26%+45.66%SLNOSoleno Therapeutics-2.85%-29.20%-30.60%-37.38%-5.83%TMDXTransMedics Group+4.25%+10.04%-6.59%-3.91%-21.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENOVEnovis 3.00Buy$51.0057.65% UpsideIRMDiRadimed 3.00Buy$72.000.69% UpsideSLNOSoleno Therapeutics 3.08Buy$115.09122.54% UpsideTMDXTransMedics Group 2.73Moderate Buy$125.403.97% UpsideCurrent Analyst Ratings BreakdownLatest IRMD, TMDX, SLNO, and ENOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/16/2025TMDXTransMedics GroupEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$155.009/10/2025SLNOSoleno TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/4/2025TMDXTransMedics GroupStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold$115.008/27/2025SLNOSoleno TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$106.008/25/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold8/20/2025SLNOSoleno TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$123.008/18/2025SLNOSoleno TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.00 ➝ $110.008/8/2025ENOVEnovisCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$70.00 ➝ $58.008/8/2025ENOVEnovisUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $57.008/8/2025ENOVEnovisWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$48.00 ➝ $41.008/7/2025SLNOSoleno TherapeuticsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENOVEnovis$2.11B0.88$19.26 per share1.68$45.10 per share0.72IRMDiRadimed$73.24M12.42$1.58 per share45.26$6.85 per share10.44SLNOSoleno TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ATMDXTransMedics Group$441.54M9.31$1.74 per share69.46$6.81 per share17.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENOVEnovis-$825.49M-$14.25N/A10.14N/A-37.80%6.78%3.73%11/5/2025 (Estimated)IRMDiRadimed$19.23M$1.6244.0635.76N/A26.61%23.30%20.62%10/30/2025 (Estimated)SLNOSoleno Therapeutics-$175.85M-$4.14N/AN/AN/AN/A-73.74%-56.67%11/5/2025 (Estimated)TMDXTransMedics Group$35.46M$1.9361.8984.34N/A13.49%28.02%8.64%10/27/2025 (Estimated)Latest IRMD, TMDX, SLNO, and ENOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ENOVEnovis$0.74$0.79+$0.05-$0.64$555.80 million$564.50 million8/6/2025Q2 2025SLNOSoleno Therapeutics-$0.53-$0.09+$0.44-$0.09$3.91 million$32.66 million7/30/2025Q2 2025TMDXTransMedics Group$0.48$0.92+$0.44$0.92$146.64 million$157.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENOVEnovisN/AN/AN/AN/AN/AIRMDiRadimed$0.680.95%N/A41.98%1 YearsSLNOSoleno TherapeuticsN/AN/AN/AN/AN/ATMDXTransMedics GroupN/AN/AN/AN/AN/ALatest IRMD, TMDX, SLNO, and ENOV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/31/2025IRMDiRadimedquarterly$0.171.13%8/18/20258/18/20258/28/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENOVEnovis0.532.251.15IRMDiRadimedN/A8.787.51SLNOSoleno Therapeutics0.2115.1315.01TMDXTransMedics Group1.619.869.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENOVEnovis98.45%IRMDiRadimed92.34%SLNOSoleno Therapeutics97.42%TMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipENOVEnovis2.70%IRMDiRadimed36.80%SLNOSoleno Therapeutics6.40%TMDXTransMedics Group7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENOVEnovis7,36757.16 million55.62 millionOptionableIRMDiRadimed11012.72 million8.04 millionOptionableSLNOSoleno Therapeutics3053.15 million49.74 millionOptionableTMDXTransMedics Group21034.09 million31.70 millionOptionableIRMD, TMDX, SLNO, and ENOV HeadlinesRecent News About These CompaniesTransMedics Group (NASDAQ:TMDX) Now Covered by Evercore ISISeptember 17 at 8:44 AM | marketbeat.comEvercore ISI Group Initiates Coverage of TransMedics Group (TMDX) with Outperform RecommendationSeptember 17 at 2:40 AM | msn.comThe Analyst Verdict: TransMedics Group In The Eyes Of 4 ExpertsSeptember 16 at 9:39 PM | benzinga.comTransMedics: Upcoming Trials Are CriticalSeptember 16 at 5:03 PM | seekingalpha.comIf You Invested $1000 In TransMedics Group Stock 5 Years Ago, You Would Have This Much TodaySeptember 16 at 11:37 AM | benzinga.comZevenbergen Capital Investments LLC Purchases New Position in TransMedics Group, Inc. $TMDXSeptember 16 at 5:55 AM | marketbeat.comThis TransMedics Group Insider Increased Their Holding In The Last YearSeptember 14 at 6:28 PM | finance.yahoo.comUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Boosts Stock Position in TransMedics Group, Inc. $TMDXSeptember 14 at 4:18 AM | marketbeat.comTransMedics Group (NASDAQ:TMDX) Trading Up 8.2% - Here's What HappenedSeptember 13, 2025 | marketbeat.comStifel Nicolaus Sticks to Its Hold Rating for TransMedics Group (TMDX)September 13, 2025 | theglobeandmail.comTD Cowen Sticks to Its Buy Rating for TransMedics Group (TMDX)September 13, 2025 | theglobeandmail.comTransMedics Group (NASDAQ:TMDX) Shares Gap Up - Here's What HappenedSeptember 11, 2025 | marketbeat.comHere’s Why Wall Street is Bullish on TransMedics Group (TMDX)September 10, 2025 | msn.comWhy TransMedics (TMDX) is a Top Growth Stock for the Long-TermSeptember 8, 2025 | zacks.comTransMedics Group, Inc. (TMDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8, 2025 | seekingalpha.comHsbc Holdings PLC Trims Position in TransMedics Group, Inc. $TMDXSeptember 7, 2025 | marketbeat.comTransMedics Group (NASDAQ:TMDX) Coverage Initiated at Stifel NicolausSeptember 7, 2025 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Now Covered by Stifel NicolausSeptember 6, 2025 | marketbeat.comComerica Bank Reduces Stock Holdings in TransMedics Group, Inc. $TMDXSeptember 6, 2025 | marketbeat.comTransMedics Group (NASDAQ:TMDX) Stock Price Down 4% - Here's What HappenedSeptember 5, 2025 | marketbeat.comStifel Initiates Coverage of TransMedics Group (TMDX) with Hold RecommendationSeptember 5, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIRMD, TMDX, SLNO, and ENOV Company DescriptionsEnovis NYSE:ENOV$32.35 -0.97 (-2.91%) As of 03:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.iRadimed NASDAQ:IRMD$71.51 +0.05 (+0.07%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.Soleno Therapeutics NASDAQ:SLNO$51.72 +2.01 (+4.04%) As of 03:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.TransMedics Group NASDAQ:TMDX$120.61 +1.46 (+1.22%) As of 03:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
